Andrea Ellis, Director at BridgeBio Pharma, Inc. (BBIO), sold 10,000 shares at $35.00 ($350K) on 2025-04-14, disclosed to the SEC on 2025-04-16.
Scheduled sale ($350k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BBIO | SELL | 2025-08-07 | $841K | — | Filing → |
| BBIO | SELL | 2025-04-03 | $2.0M | — | Filing → |
| BBIO | BUY | 2022-03-17 | $101K | — | Filing → |